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Abstract Hypertension and proteinuria are commonly observed side-effects for
anti-angiogenic drugs targeting the VEGF pathway. In most cases, hypertension can
be controlled by prescription of anti-hypertensive (AH) therapy, while proteinuria
often requires dose reductions or dose delays. We aimed to construct a pharma-
cokinetic–pharmacodynamic (PK–PD) model for hypertension and proteinuria
following treatment with the experimental VEGF-inhibitor E7080, which would
allow optimization of treatment, by assessing the inﬂuence of anti-hypertensive
medication and dose reduction or dose delays in treating and avoiding toxicity. Data
was collected from a phase I study of E7080 (n = 67), an inhibitor of multiple
tyrosine kinases, among which VEGF. Blood pressure and urinalysis data were
recorded weekly. Modeling was performed in NONMEM, and direct and indirect
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DOI 10.1007/s10928-010-9164-2response PK–PD models were evaluated. A previously developed PK model was
used. An indirect response PK–PD model described the increase in BP best, while
the probability of developing proteinuria toxicity in response to exposure to E7080,
was best described by a Markov transition model. This model may guide clinical
interventions and provide treatment recommendations for E7080, and may serve as
a template model for other drugs in this class.
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Introduction
Over the last few decades, various pharmacological approaches to the inhibition of
angiogenesis have been investigated. So far, suppression of vascular endothelial
growth factor (VEGF) signaling has shown the most prominent clinical success.
This can be achieved by drugs that inhibit signaling by binding the tyrosine kinase
domains of the VEGF-Receptor (VEGFR) such as sorafenib, or binding to VEGF by
monoclonal antibodies (e.g. bevacizumab) or decoy receptors (VEGF-Trap). While
drugs acting on the VEGF pathways are generally well tolerated at doses that
achieve pharmacologically active plasma levels, especially in comparison with
classical cytotoxic drugs, toxicities are still a major problem. This may partially be
explained by the fact that VEGF-signaling is not speciﬁc to tumor-induced
angiogenesis, but is also involved in various other physiological mechanisms.
Furthermore, most small-molecule VEGF(R)-inhibitors are not speciﬁc for the
tyrosine kinase domain of one speciﬁc receptor, but may interfere with multiple
pathways. The most commonly reported side effects for VEGF(R)-inhibitors are
hypertension and proteinuria [1]. While the observed hypertension can generally be
managed with anti-hypertensive (AH) drugs, proteinuria is often treatment limiting,
and necessitates dose interruptions or dose reductions. Several mechanisms are
assumed to be involved in the development of hypertension, including the decrease
of NO and/or PGI2 production, rarefaction of blood vessels, vascular stiffness and
disturbed endothelin function, although the exact mechanisms has not been clariﬁed
yet [2]. Proteinuria may be caused directly by drug action through inhibition of
VEGF’s effects on glomerulal endothelial function, or indirectly through increase of
blood pressure, but most probably a combination of both factors is involved.
Although tyrosine kinase inhibitors (TKI) are targeted molecules, and often show
efﬁcacy at lower concentrations than achieved using the approved doses, it is
recognized that dosing should be aimed at obtained as high exposure as possible [3].
Therefore, clinical development of these agents often adheres to comparable
strategies as those of cytotoxic anti-cancer agents, i.e. aimed at ﬁnding a maximum
tolerable dose (MTD). This implies that still a signiﬁcant number of patients will
experience toxicities in treatment with these agents, thereby potentially limiting
treatment efﬁcacy due to dose reductions or dose delays. The management and if
possible avoidance of these toxicities is therefore of key importance. Moreover, a
positive correlation has been shown between the development of hypertension and
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123treatment effect, and, therefore, it has been proposed that hypertension might
function as a biomarker to guide individual dosing strategies [4–7].
In this article we report the development of a pharmacokinetic–pharmacody-
namic (PK–PD) model that describes the effects of exposure to a novel drug
targeting the VEGF pathway (E7080) on blood pressure and the probability of
developing different grades of proteinuria, in patients with cancer. E7080 is an oral
anti-cancer agent, inhibiting angiogenesis by its capacity to bind tyrosine kinase
domains of several receptors, mainly VEGF-R2 and VEGF-R3 [8]. In preclinical
trials, it has shown promising activity, and was shown to be more potent than
bevacizumab in reducing angiogenesis and lymph angiogenesis in xenograft models
[8, 9]. E7080 has been tested in several Phase I trials, in which both hypertension
and proteinuria were commonly observed and were the major dose limiting toxicity.
By developing this model, we aim to provide a tool to investigate the inﬂuence of
dosage, exposure, time, and patient characteristics on the development of these
toxicities. The model will allow evaluation of dosing regimens for reduction of
adverse events or optimizing efﬁcacy, support clinical decision making, and aid in
further clinical development of this drug.
Methods
Data
Data was obtained from a two-site phase I dose ﬁnding study of E7080 in patients
with advanced malignancies, as described elsewhere [10–12]. In summary, patients
were C18 years of age with solid tumors or lymphoma, and a Karnofsky score
C70%. Patients were treated with E7080 once daily (qd), using ﬁxed doses. No
other anti-cancer drugs were administered during or less than 4 weeks before start
of treatment. Doses were escalated from 0.2 mg day
-1 up to 32 mg day
-1 in
cohorts of 3–6 patients. Intra-patient dose escalation was not allowed. Relevant
exclusion criteria were brain tumors, uncontrolled infections, reduced bone marrow
reserve, clinically signiﬁcant cardiac impairment, and bleeding or thrombotic
disorders. Excluded were patients using therapeutic dosages of anti-coagulants,
patients treated with other investigational drug within 30 days prior to start of study,
patients with proteinuria C2? (CTC grade C2), and patients with poorly controlled
hypertension (repeated measurements higher than 160/90 mmHg) at screening.
AH therapy was offered to all patients who had a conﬁrmed blood pressure (BP)
of 160/100 mmHg during treatment with E7080. If BP during treatment was[160/
100 mmHg, AH therapy was initiated according to local guidelines, with the aim of
reducing BP to B140/90 mmHg. E7080 dose reductions following adverse events
were performed per protocol, to 75 or 50% of the former dose, or discontinuation of
treatment, depending on the grade of toxicity and the number of times the toxicity
grade occurred before.
PK samples were obtained after the ﬁrst dose at day 1 of cycle 1 and cycle 2.
Trough samples were obtained on days 8, 15 and 22 of cycle 1, and on the ﬁrst day
of each subsequent schedule. Plasma concentrations were determined using a
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out weekly using standard manual sphygmomanometers. From all patients, the
medication prescriptions were recorded during the study. Prescription of anti-
hypertensive (AH) drugs, or drugs that were known to induce anti-hypertensive
effects was recorded.
Urinalysis was performed weekly during therapy using commercially available
strip tests, and consisted of (at least) pH, glucose, protein measured by dipstick,
presence of ketones, and presence of blood. Protein in urine was reported as
‘negative’, ‘trace’, ‘?/-’, ‘?’, ‘2?’, ‘3?’o r‘ 4 ?’, but treated as a four category
scale, corresponding to the CTC (NCI, version 3.0) grades: PU1 =\1?,
PU2 = 1?,P U 3 = 2? or 3?,P U 4 = 4?.
PK–PD analysis
The statistical data analysis was performed with non-linear mixed effects modeling
using NONMEM, version VI, level 2.0 (Icon Development Solutions, Ellicott City,
MD, USA) with g77 as Fortran compiler, using several functions from the PsN
toolkit [13], and Piran ˜a[ 14] as modeling environment. The ﬁrst order conditional
estimation method with interaction (FOCE-I) was used throughout the analysis. The
Laplacian method was uses for modeling the categorical data. When continuous and
categorical data were modeled simultaneously, the F_FLAG option was used to
switch between observations and likelihoods. Standard errors for model parameters
were estimated from the covariance step in NONMEM.
Judgement of model ﬁt was done using goodness-of-ﬁt plots, the likelihood ratio
test (LRT), and measures of model stability and adequacy (condition number,
successful convergence, signiﬁcant digits, matrix singularity). Nested models were
tested for signiﬁcant improvement in ﬁt at a signiﬁcance level of P\0.01,
corresponding to a decrease in objective function value (OFV) of 6.67. Plots of
conditional weighted-residuals (CWRES) versus time and versus predicted values
were used to evaluate model bias.
Performance of candidate and ﬁnal models for the BP model was evaluated using
visual predictive checks (VPC), by simulation of 500 simulated datasets [15]. Since
observations were spread around nominal time points, bin separators in the VPC
were set at the lowest densities of sample points over time, i.e. this positions the bins
such that the periods with densest sampling were in the middle of the bins.
Shrinkage in between subject variability (BSV) and residual errors was calculated to
assess the informativeness of the data for using individual predications in the
evaluation of model ﬁt. The adequacy of the model for prediction of probabilities of
developing proteinuria grades was also evaluated by VPCs, i.e. the observed
percentage of patients experiencing a speciﬁc CTC grade were compared with those
simulated from the model in simulated datasets of which median, and 95%
prediction interval (PI) were calculated. The ability of the model to predict
individual patterns of proteinuria grades in patients was evaluated, by comparing
longitudinal plots of several simulated datasets for proteinuria with the observed
data. Also, predictive checks were performed by simulating 200 new datasets with
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to another, with the observed.
The PK–PD model was developed using a sequential approach, i.e. the empirical
Bayesian estimates (EBE) from a previously developed PK model [7] were used to
drive the BP model. Brieﬂy, the PK model consisted of a central and a peripheral
compartment, with a sequential zero- and ﬁrst-order absorption process and ﬁrst
order elimination. E7080 was rapidly absorbed (ka = 0.348) with maximum
concentrations typically observed from 1 to 3 h post dose, and clearance was linear
over the studied dose range (CLpop = 6.07 l h
-1, Vcentr = 11.3 l, Q = 3.95,
Vper = 45.3). After development of the BP model, the EBEs from the BP model
were used in the development of the model for proteinuria. In a ﬁnal step, both PD
models (hypertension and proteinuria) were also ﬁtted simultaneously.
BP model
Several structural models were tested for the BP model, expressed as direct effects
or indirect responses. The indirect response models were implemented as
differential equations (ODE): an effect-compartment model [16], a turnover-model
[17], or a combined effect-compartment and turnover model. Since the BP data
consisted of systolic (BPS) and diastolic (BPD) blood pressure data, we evaluated
two methods of incorporating both data sources. Firstly, BPS was modeled as
function of drug effect, with BPD data assumed to be proportional to BPS, or the
other way around. Secondly, we evaluated a model that incorporated two separate
indirect effect models for BPS and BPD.
Additive, proportional, combined additive and proportional, and exponential
(using untransformed data) residual error models were evaluated. As residual errors
for BPS and BPD recorded at the same timepoint might be expected to show
correlation, the L2 data item implemented in NONMEM was used, which groups
these data in a second level of random effects, allowing the estimation of this
correlation magnitude. Several approaches for implementing BP at baseline were
tested, as described by Dansirikul et al. [18].
Drug effect (EE7080) and effect of AH medication (EAH) were incorporated as
slope effect on rate constants in the BP indirect effect model as shown in Eq. 1 for
the systolic compartment:
dBPS
dt
¼ kin  
1 þ EE7080 ðÞ
1 þ EAH ðÞ
  kout   BPS ð1Þ
In this equation, both baseline and kin were estimated, and kout was ﬁxed to kin/BPS,
thereby not allowing for spontaneous increase or decrease from baseline. EE7080 was
deﬁned as a slope function: EE7080 = hx   cp,E7080, and EAH was estimated as a slope
function on cumulative AH prescription, while Emax models were also evaluated. At
baseline, the system was assumed to be at steady state, i.e. kout was set to kin/BPs,base
Models that incorporated EE7080 and EAH on kout instead of on kin were also
assessed. A cumulative measure of AH prescription as ‘deﬁned daily dose equiv-
alents’ was constructed, as
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X n
1
DDi
DDDi
ð2Þ
scaling the daily prescribed dose (DD) to its WHO deﬁned daily dose (DDD,
http://www.whocc.no/atcddd/indexdatabase/, accessed November 11, 2008), over
the n different AH medications that the patient was using at a certain timepoint. It
was also evaluated if the inclusion of the effect of AH treatment as a direct effect,
i.e. on the error model, resulted in similar or improved model ﬁt. The equation thus
uses as differential equation for BPS and BPD was:
dBPS
dt
¼ kin  
1 þ h1   cp;E7080
  
1 þ h2   DDDEAH ðÞ
  kout   BPS ð3Þ
with h1 and h2 being the estimated slopes of the effects of drug and anti-
hypertensive treatment.
Proteinuria
For describing the observed categorical PU data, two approaches were evaluated.
First, a proportional odds model was implemented in which three probabilities had
to be estimated, as proteinuria was divided in four ordered categories (the fourth can
be deducted as one minus the cumulative probabilities of the other grades). A logit
transformation was applied to constrain estimated probabilities between 0 and 1,
using:
LogitðpiÞ¼ln
Bi þ f
1 þ Bi þ f ðÞ
  
ð4Þ
with i 2½ 1;3 , and Bi the offset probabilities for the different CTC grades (on a logit
scale). The function f was used to link drug effects to probabilities of developing
proteinuria, in which both linear and Emax equations were investigated.
Secondly, a Markov transition model was implemented. Study protocol
indicated that urinalyses were to be performed weekly, however in clinical
practice it was observed that the observations were not equally spaced. To be able
to calculate the probabilities of observing each grade at every timepoint, the
probabilites were incorporated in the model as differential equations (see Fig. 1).
The probability at t = 0 was set to 1 for the observed proteinurea state at baseline,
and updated after each observation. To reduce the number of parameters to
estimate, only transitions between neighboring states were included in the model.
Evaluation of the effects of drug exposure, blood pressure, and AH medication on
transition were implemented in the Markov model using as proportional factors on
the transitions rate parameters.
k0!1 ¼ hx   Edrug   EAH   EBP ð5Þ
All effect parameters were tested on each transition parameter separately, and in
combination. The effects were included on the transitions for increasing transitions
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k3?2) separately. It was tried to reduce the number of parameters, by including the
same factors reciprocally for the transitions for decreasing grades, e.g.:
k1!0 ¼ hx   E 1
drug   E 1
AH   E 1
BP ð6Þ
Drug effect on probability of developing proteinuria was tested in several ways. A
direct drug effect was incorporated by relating predicted plasma concentrations (cp)
using slope or Emax factors to probabilities (in the proportional odds model) or
transition rates (in the Markov model). An indirect effect was incorporated as an
exposure compartment, i.e. the area under the concentration–time curve, with-
(AUCEE7080, ‘‘effect compartment’’) and without (AUCE7080, ‘‘cumulative expo-
sure’’) an estimated ﬁrst-order recovery rate. Increases in BPD and BPS from
baseline were also evaluated as covariate on the transition rates. Co-medication that
were plausible to have an effect on proteinuria were included as a binary covariate
(use or no-use of medication). These included: anti-hypertensive medication,
aldosterone-blocking drugs, diuretic drugs, non-steroidal anti-inﬂammatory drugs
and bisphosphonates [19]. Furthermore, a number of additions to the PK–BP–
proteinuria base model were considered. These included e.g. the development of
tolerance, and the incorporation of lag-times before onset of the hypertensive effect
of exposure to E7080 improved model-ﬁt, either related to time, cumulative AUC or
both).
kin kout
Pharmacokinetics
AH
AH
Pr (PU)
Central Periph
Dose
E7080
BPsys
BPdia
AUCE
Pharmacodynamics
PU0
PU1
PU2
PU3
Proteinuria Markov model
- +
- +
- +
Fig. 1 PK–PD model for E7080. At t = 0, proteinuria (PU) compartment amounts are set to 0 or 1
according the observed proteinuria grade at baseline
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Patients and data
Patient characteristics are given in Table 1. BP and data from urinalysis were
recorded over a mean period of 24 weeks (range 1–77 weeks). None of the patients
experienced grade 4 hypertension or grade 4 proteinuria toxicities. The maximum
tolerable dose (MTD) was established at 25 mg day
-1.
BP model
In Fig. 1, the ﬁnal structural PK–PD model is shown. It was found that indirect
response models provided better ﬁt than direct effect models. Two separate indirect-
effect models for BPS and BPD best described the data. A combination of direct and
indirect response models did not provide better ﬁt than indirect response alone.
Baseline BPS and BPD were estimated at 126 and 77.2 mmHg (RSE \5%)
respectively, with 10% (RSE 12%) BSV for both BPS and BPD. The plasma
concentration of E7080 (cp,E7080) was linked to the input rate of the indirect effect
model by a slope factor, which could be estimated separately for BPS and BPD. These
effects differed signiﬁcantly for BPS and BPD, but lead to approximate similar
absolute effect sizes (in mmHg). An Emax model for the concentration–effect
relationship was not supported by the data. BSV on drug effect was estimated almost
three times larger for BPS (72%, RSE 40%) than for BPD (26%, RSE 50%), with a
Table 1 Patient and study
characteristics N/Mean Range
Male 38
Weight (kg) 79.3 48.3–121
Female 29
Weight (kg) 73.9 51.4–114
Age (years) 55 25–84
Race
Caucasian 66
Black 1
BPS at baseline (mmHg) 130.7 99–170
BPD at baseline (mmHg) 76.5 51–105
Time in study (weeks) 24 1–77
Patients using AH medication at baseline 3
Patients using AH medication in study 8
Proteinuria toxicities (n observations)
Grade 0/no toxicity 1042
Grade 1 202
Grade 2 75
Grade 3 9
Grade 4 0
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describedusingAHdailydoseequivalents.TheeffectofAHtherapywaslinkedtothe
input rates of the indirect response model for BP by a slope factor, estimated at 0.036
DDDE
-1, which could not be estimated separately for BPS and BPD. Due to the low
number of patients (n = 8) receiving AH medication in the study, BSV could not be
estimated for the effect of AH drugs. Moreover, for the same reason, and since the
prescribed medication was too diverse, class differences in effects between AH drug
classes could not be assessed.
From the hospital information system we could retrieve the actual time of day at
which the BP recordings were taken for about 25% of the dataset. However, all of
these measurements, and therefore likely also the actual times of BP recordings that
were not retrievable, were obtained in a narrow time window (between 9 AM and 12
AM). This precluded an informative assessment of 24-h blood proﬁles [20].
An exponential residual error model best ﬁtted the model prediction to the data.
The overall exponential residual error magnitude for BPS and BPD was 12.8% (RSE
3%), with 53% (RSE 3%) correlation between systolic/diastolic residual errors
recorded at the same timepoint. Residual error magnitude was the same for BPS and
BPD. The inclusion of BSV on the residual error magnitude improved ﬁt of the
model signiﬁcantly, and was estimated at 12% (RSE 23%). The model for BP did
not show signiﬁcant bias judged by inspection of plot of CWRES vs time or
predicted BP (not shown).
Proteinuria
In the proportional odds model, AUCEE7080 (‘‘effect compartment’’) was a
signiﬁcant better predictor for the probability of developing proteinuria than
AUCE7080 (‘‘cumulative exposure’’). Furthermore, BPD was a signiﬁcant better
predictor than BPS, and inclusion of both AUCEE7080 and BPD parameters
simultaneously showed signiﬁcantly better ﬁt than when included separately. Both
predictors could only be related to the probabilities using a slope model, Emax
models were not supported by the data. Development of tolerance or lag-times in the
onset of proteinuria did not signiﬁcantly improve the model. A VPC of the
proportional odds model (not shown) showed good agreement between observed
and model predicted numbers of patients experiencing different proteinuria grades.
However, a predictive check of the number of transitions revealed that the number
of transitions between grades was signiﬁcantly overpredicted by the model for most
transitions.
Therefore, a Markov transition model was also implemented and evaluated. Since
the number of observed grade 3 proteinuria toxicities was low (n = 9), transition
rates to- and from grade 3 could not be estimated independently, and k2?3 was ﬁxed
to 0.2 weeks
-1, which allowed estimation of all other transition rates. By inspection
of predictive checks, it was assured that the correct number of transitions to and
from grade 3 were predicted by the model. BSV in the drug effect or in the transition
rates could not be estimated. Addition of parameters to describe the drug effect
more speciﬁcally in the Markov model, e.g. separately on each transition and/or
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improve the model.
In the Markov model, as in the proportional odds model, an indirect drug effect
(AUCEE7080) described the data signiﬁcantly better than when no drug effect or only
a direct effect was implemented. The half-life for the recovery rate of the exposure
compartment was estimated at 98.1 days, suggesting an almost cumulative effect
(AUC) of drug exposure on proteinuria. The exposure was however signiﬁcantly
better than when included as an effect of total AUC. Blood pressure, either BPS or
BPD included as covariate on transition rates, improved model ﬁt, although the
improvement was not signiﬁcant nor relevant, and destabilized the Markov model,
and was therefore not included as predictor in the proteinuria model. Incorporation
of AH medication as protective time-changing covariate improved the ﬁt slightly in
both the Markov model and the proportional odds model, but the effect was not
signiﬁcant. Co-medication did not affect the probabilities for experiencing
proteinuria.
A VPC (Fig. 3) of the Markov model showed that on a population level, the
model predicted the % of patients experiencing the PU grades just as good as the
proportional odds model. However, a predictive check for all transitions of the
Markov model, shown in Fig. 4, showed much better agreement between observed
and predicted number of transitions between toxicity grades than the proportional
odds model. For almost all transitions, the observed number was within the 90%
(PI) of the model. Therefore the Markov model was chosen as ﬁnal model for
describing PU toxicities.
Parameter estimates for the ﬁnal model are presented in Table 2, together with
their relative standard errors. The %RSE of both ﬁxed effects parameters were low
to intermediate, indicating that the model parameters could be estimated with
adequate precision. Model stability of the ﬁnal model was indicated by successful
convergence of the estimation procedure, successful implementation of the
covariance step, and low condition numbers of the model (62 for the BP model,
63 for the proteinuria Markov model). For the random effects the amount of
shrinkage is also shown in Table 2, which was low for BSV in baseline BP, but
intermediate to high for residual error and BSV in EE7080.
Discussion
Hypertension and proteinuria are commonly observed side effects of mAbs and
TKIs directed against VEGF or the VEGF receptor. Meta-analysis showed a
22.5–57.7% incidence of hypertension in studies with angiogenesis inhibitors, and a
7.5, 6.1 and 22.7 relative risk of developing hypertension for bevacizumab,
sorafenib and sunitinib, respectively [21–23]. The mechanisms through which the
hypertensive effect is mediated are still subject of discussion. Physiologically,
VEGF stimulates the production and release of vasodilatory stimulants NO by
endothelial cells through stimulatory action on endothelial nitric oxide synthase
(eNOS). Inhibition of VEGF signaling will hence lead to decreased release of NO
and higher vascular resistance. Rarefaction of microvascularity, i.e. a reduced
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hypertension [24]. For sorafenib, it has been postulated that increased vascular
stiffness is the primary cause of elevated blood pressure [25].
Hypertension is known to be strongly correlated to the development of
proteinurea [26]. Moreover, since VEGF has an important role in the homeostasis
of glomerulal endothelial cells, VEGF inhibitors may have direct effects on
the development of proteinurea, apart from their effect through BP elevation. In a
Table 2 Model estimates
Parameter Description Estimate RSE Shrinkage
(%)
BP model
BPS,base Baseline systolic BP 126 mmHg (1%)
BPD,base Baseline diastolic BP 76.8 mmHg (1%)
kin Input rate indirect effect model 0.304 mmHg h
-1 (18%)
EE7080,S Drug effect on systolic input rate 0.543 ng
-1 ml (19%)
EE7080,D Drug effect on diastolic input rate 0.904 ng
-1 ml (13%)
EAH Effect of AH medication 36 DDDE
-1 (–)
Markov PU model
Eindir Indirect effect size 1.09 9 10
-3 ng
-1 h
-1 ml (51%)
Edir Direct effect size 2.2 ng
-1 ml (–)
t1/2,indir Half-life of recovery 98 days (47%)
k0?1 Transition rate from state 0 to 1 0.141 week
-1 (22%)
k1?0 Transition rate from state 1 to 0 1.19 week
-1 (19%)
k1?2 Transition rate from state 1 to 2 0.361 week
-1 (40%)
k2?1 Transition rate from state 2 to 1 1.90 week
-1 (41%)
k2?3 Transition rate from state 2 to 3 0.20 week
-1 (ﬁxed)
k3?2 Transition rate from state 3 to 2 4.97 week
-1 (74%)
BSV
BSV: BPS BSV in systolic blood pressure 10% (12%) 4.9
BSV: BPD BSV in diastolic blood pressure 9% (13%) 6.2
BSVcorr,BP Correlation in baseline between
BPsys–BPdia
8% (16%)
BSV: EE7080,S BSV in drug effect on systolic
input rate
66% (41%) 45
BSV: EE7080,D BSV in drug effect on systolic
input rate
39% (47%) 51
BSVcorr,E Correlation in drug effect sizes
BPsys–BPdia
32% (71%)
BSVRE BSV in RE 12.4% (22.8%) 32
RE
RE Exponential residual error 12.8% (3%) 28
Corr RES–RED Correlation residual errors
for BPsys–BPdia
53.5% (3%)
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proteinuria was investigated [21]. Although an association between hypertension
and proteinuria was found, the authors were unable to dissect if proteinuria was
caused by hypertension, or directly by exposure to bevacizumab resulting from
VEGF blockade, or through both mechanisms.
The development and approval of several new angiogenesis inhibitors over the
last few years, and the shared toxicity proﬁle, has prompted us to construct a model
that describes hypertension and proteinuria toxicities observed for agents in this
class of drugs. In treatment with TKIs it is attempted to achieve as high exposure as
possible, i.e. dosing at the MTD. Moreover, hypertension is recognized to be a
biomarker for treatment efﬁcacy with angiogenic agents. Investigation of strategies
to avoid, cope with or diminish toxicities will help to maximize exposure to these
drugs, and consequently increase treatment response. Recently, a model was
presented describing time proﬁles of blood pressure and pharmacodynamic
biomarkers in response to administration of sunitinib [27]. This model was shown
to be predictive of blood pressure proﬁles in patients treated with sunitinib [28],
although it did not incorporate the occurrence of proteinuria, nor interventions with
AH medication.
The model presented in the current article was constructed on the basis of clinical
data, and was able to capture the rise in blood pressure, and the increased
probability of experiencing grades of proteinuria, in response to treatment with
E7080, an inhibitor of VEGF. We expect this model to be applicable to other anti-
angiogenic agents as well. If so, this will require the collection of PK, BP and
proteinurea data from treatment with those compounds. As the link between
exposure and PD effects in our model is not mechanistic, these cannot easily be
extrapolated from preclinical data. However, as no mechanisch link is present, the
model structure presented in this article may be applied to other exposure–effect
relations as well, such as changes in biomarkers or disease states due to drug
treatment.
PK–PD analysis
An issue that may have inﬂated the residual error of the model is the fact that the BP
recordings are not a truly continuous data source: clinicians and nurses tend to round
BP to the nearest 5 mmHg unit. In theory, this should not introduce bias, although it
may decrease precision. Furthermore, since BP shows pronounced diurnal patterns,
the time of day of BP measurement is important, not only in diagnosing
hypertension, but also in ﬁtting models for BP, since this will introduce bias and
imprecision if not accounted for. Addition of circadian variation to the current
template model may be a valuable addition, if exact times of measurement are
available.
The number of patients that were prescribed AH medication at some point during
the treatment course was low (n = 8) in this study. This was partially because data
were obtained from a dose escalation study: a considerable portion of the patients
were treated at E7080 dose levels that did not show hypertension or proteinuria
toxicities. Due to this low number of patients and the diversity in their AH
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123medication (four different classes, doses ranging from 0.25 to 4 DDDE), a thorough
assessment of the effect of AH medication was not possible from the current data.
Therefore, if this model is used in a simulation analysis, e.g. to assess the effect of
different hypertension intervention strategies, these results should be interpreted
with some caution.
Fig. 3 VPC of the Markov transition model for proteinuria grades (split in two to avoid overlap of the
prediction intervals). The grey areas show the 90% prediction interval for the % of patients experiencing
PU, while the dotted line represents the model predicted median. Solid lines are observed % of proteinuria
grades
Fig. 2 Visual predictive checks of systolic (a) and diastolic (b) BP, for patient treated at the MTD of
25 mg E7080 qd. Solid line and dark grey area represents median observed and predicted 95% CIs.
Dashed lines and light grey areas represent the 10 and 90% percentiles of the observed values, and the
95% CI of the model predicted percentiles
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In our analysis we found a probability at baseline of experiencing C1 ? proteinurea
(CTC grade C1) as measured by dipstick that was 15%. It has been shown that
incidence of proteinuria is signiﬁcantly higher in patients with malignancies than in
healthy controls [29]. In our analysis of proteinuria data we could distinguish an
effect of E7080 plasma concentration on the occurrence of this toxicity, as well as a
separate effect mediated by an increased BPD. The latter effect was however only
signiﬁcant when a proportional odds model was used, and not when the Markov
model was used. Analysis of data from future trials with the current model may be
able to address in more detail how the effect on proteinuria is mediated.
Treatment with AH drugs, especially ACE-inhibitors and agiotensin II receptor
blockers, is known to reduce proteinuria in both hypertensive [30] and normotensive
patients [31]. Due to the low overall size of the study and the percentage of patients
that were prescribed AH medication, we were unable to show any signiﬁcant effect
of AH medication on the development of proteinuria, let alone assess class
differences between AH drugs. Data from subsequent trials will be needed to assess
the inﬂuence of covariates, such as genetic predispositions and/or baseline
Fig. 4 Predictive check of Markov model transitions. Histograms represent the model simulated
(n = 200) transitions. The dashed lines represents the 5th and 95th percentiles of the simulated number of
transitions
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123characteristics that might predispose patients to developing proteinuria. The number
of patients experiencing grade 3 neutropenia was low, thereby limiting the ability to
rigorously test the validity of our model for predicting grade 3 PU toxicity.
Although we considered lumping the grade 2 and grade 3 toxicities in one category,
it was chosen not do so because clinically, the distinction between grade 2 and grade
3 PU is important for interventions. The probabilities associated with developing
grade 4 proteinuria could not be estimated, since this grade was not observed in the
clinical trial.
Overall, although the dataset was obtained from a single phase I study, the dose
range that was studied provided enough data to capture an exposure–response
relationship, both for BP and for the probability of experiencing proteinuria. The
predictive checks that were generated (Figs. 2, 3, 4) showed that the model was
describing the observed clinical data with satisfactory precision, which is especially
important if the model is to be used for simulation purposes, e.g. the evaluation of
dosing strategies. Such simulations have been planned, and include e.g. the
evaluation of a hypertension intervention scheme, and the evaluation of an adaptive
treatment design, using BP to guide intra-patient dose escalation.
Conclusion
In this article we presented a model that was able to capture the pharmacodynamic
characteristicsofanoveloralanti-canceragent(E7080)targetingtheVEGFpathway.
This model, willallowthe investigationofclinicalstrategiesforoptimizingtreatment
with E7080. The current model was constructed using data from a single anti-
angiogenic TKI, but may serve as a template model for hypertension and proteinuria
toxicity in treatment with drugs targeting the VEGF pathway.
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